Last reviewed · How we verify
TNF Inhibitor (tnf-inhibitor)
Pfizer's TNF Inhibitor is a marketed drug with a revenue of $21.2B. It is used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, and Crohn's Disease. The drug has undergone 100 trials and has 1313 publications. It is a monoclonal antibody that targets TNF-alpha, a key cytokine involved in inflammation. This mechanism allows it to reduce inflammation and slow disease progression. The commercial significance of TNF Inhibitor lies in its ability to provide relief to millions of patients worldwide. Pfizer continues to develop its pipeline, including potential new indications and formulations for TNF Inhibitor.
At a glance
| Generic name | tnf-inhibitor |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal Antibody |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Ulcerative Colitis
- Crohn's Disease
- Plaque Psoriasis
- Juvenile Idiopathic Arthritis
- Axial Spondyloarthritis
- Psoriatic Arthritis with Distal Interphalangeal Involvement
- Moderate to Severe Ulcerative Colitis
- Non-Radiographic Axial Spondyloarthritis
- Moderate to Severe Plaque Psoriasis
- Active Ankylosing Spondylitis
- Moderate to Severe Crohn's Disease
- Moderate to Severe Rheumatoid Arthritis
- Active Psoriatic Arthritis
- Moderate to Severe Juvenile Idiopathic Arthritis
- Active Ulcerative Colitis
- Active Crohn's Disease
- Active Plaque Psoriasis
Common side effects
- Upper respiratory tract infection
- Bronchitis
- Urinary tract infection
- Rheumatoid arthritis
- Fall
- Herpes zoster
- Nasopharyngitis
- Hypertension
- Arthralgia
- Lymphopenia
- Back pain
- Diarrhoea
Drug interactions
- Abatacept
- Anakinra
- Azathioprine
- Cyclophosphamide
- Cyclosporine
- Glatiramer
- Hydroxychloroquine
- Immunosuppressants
- Live vaccines
- Methotrexate
- Mycophenolate
- Rituximab
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF Inhibitor CI brief — competitive landscape report
- TNF Inhibitor updates RSS · CI watch RSS
- Pfizer portfolio CI